Off-Label Uses of Biologic Agents in Dermatology: A 2006 Update

Seminars in Cutaneous Medicine and Surgery

Volumn 25, Issue 4, 2006, Pages 226-240

  Kerns, Mary Jo J ^a   Graves, Julia E ^b   Smith, David I ^b   Heffernan, Michael P ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALEFACEPT; ANTIBIOTIC AGENT; AZATHIOPRINE; CARIMUNE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; EFALIZUMAB; ETANERCEPT; ETRETIN; GLUCOCORTICOID; HUMAN IMMUNOGLOBULIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERFERON; ISOTRETINOIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; ORAL CONTRACEPTIVE AGENT; PANGLOBULIN; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GRAFT VERSUS HOST DISEASE; ALOPECIA AREATA; ANCA ASSOCIATED VASCULITIS; ANGIONEUROTIC EDEMA; APHTHOUS STOMATITIS; ATOPIC DERMATITIS; B CELL LYMPHOMA; BEHCET DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CHURG STRAUSS SYNDROME; CONTINUOUS INFUSION; CROHN DISEASE; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INDICATION; DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS; EOSINOPHILIA; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMA; ERYTHEMA ANNULARE CENTRIFUGUM; ERYTHEMA NODOSUM; FOOD AND DRUG ADMINISTRATION; GIANT CELL ARTERITIS; GRANULOMA ANNULARE; HAILEY HAILEY DISEASE; HUMAN; KAPOSI SARCOMA; LEUKOCYTOCLASTIC VASCULITIS; LICHEN PLANUS; LOW DRUG DOSE; MICROSCOPIC POLYANGIITIS; MIXED CONNECTIVE TISSUE DISEASE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NECROBIOSIS LIPOIDICA; NEPHROGENIC FIBROSING DERMOPATHY; OFF LABEL DRUG USE; PEMPHIGOID; PEMPHIGUS; PITYRIASIS RUBRA PILARIS; POLYARTERITIS NODOSA; PSORIASIS; PYODERMA GANGRENOSUM; RETICULOHISTIOCYTOSIS; REVIEW; SARCOIDOSIS; SCLERODERMA; SCLEROMYXEDEMA; SKIN ALLERGY; SKIN DISEASE; SKIN GRANULOMA; SKIN LUPUS ERYTHEMATOSUS; SUBCORNEAL PUSTULAR DERMATOSIS; SUPPURATIVE HIDRADENITIS; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; WEGENER GRANULOMATOSIS;

DERMATOLOGIC AGENTS; DERMATOLOGY; DRUG APPROVAL; DRUG LABELING; HUMANS; RISK FACTORS; SKIN DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33845422588     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2006.08.006     Document Type: Review

References (353)

1. Nickoloff B.J., and Stevens S.R. What have we learned in dermatology from the biologic therapies?. J Am Acad Dermatol 54 suppl (2006) S143-S151
2. Reichrath J., Bens G., Bonowitz A., et al. Treatment recommendations for Pyoderma gangrenosum an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 153 (2005) 273-283
3. Sacher C., and Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol 6 (2005) 93-103
4. Stern D.K., Tripp J.M., Ho V.C., et al. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 23 (2005) 259-300
5. Trent J.T., and Kerdel F.A. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs 17 (2005) 97-107
6. Humira (adalimumab) current prescribing information
7. Amevive (Alefacept) current prescribing information
8. Raptiva (Efalizumab) current prescribing information
9. Enbrel (etanercept) current prescribing information
10. Remicade (infliximab) current prescribing information
11. Gammagard (IVIg) current prescribing information
12. Gamunex (IVIg) current prescribing information
13. Carimune (IVIg) current prescribing information
14. Xolair (Omalizumab) current prescribing information
15. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
16. Rituxan (Rituximab) current prescribing information
17. Leynadier F., Doudou O., Gaouar H., et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 113 (2004) 360-361
18. Yeung-Yue K. Clinical improvement and apparent resolution of allergic contact dermatitis with alefacept. J Am Acad Dermatol 54 (2006) AB92 (poster abstract)
19. Heffernan M.P., Hurley M.Y., Martin K.S., et al. Alefacept for alopecia areata. Arch Dermatol 141 (2005) 1513-1516
20. Strober B.E., Siu K., Alexis A.F., et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open label study. J Am Acad Dermatol 52 (2005) 1082-1084
21. Vujevich J., and Zirwas M. Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis 76 (2005) 129-132
22. Krathen R.A., and Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53 (2005) 338-340
23. Lane J.E., Cheyney J.M., Lane T.N., et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54 (2006) 68-72
24. Cassano N., Loconsole F., Coviello C., et al. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 19 (2006) 237-240
25. Jacobi A., Antoni C., Manger B., et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52 (2005) 522-526
26. Buka R.L., Resh B., and Roberts B. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 53 (2005) 358-359
27. Hamilton T. Successful treatment of atopic dermatitis with efalizumab. J Am Acad Dermatol 54 (2006) AB87 (poster abstract)
28. Paul C., Lahfa M., Bachelez H., et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 147 (2002) 518-522
29. Jolles S., Sewell C., Webster D., et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Dermatol Venereol 83 (2003) 433-437
30. Huang J.L., Lee W.Y., Chen L.C., et al. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 84 (2000) 345-352
31. Kimata H. High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 70 (1994) 335-336
32. Jolles S., Hughes J., and Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 142 (2000) 551-554
33. Wakim M., Alazard M., Yajima A., et al. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 81 (1998) 153-158
34. Gelfand E.W., Landwehr L.P., Esterl B., et al. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 104 suppl (1996) 61-66
35. Melikoglu M., Fresko I., Mat C., et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 32 (2005) 98-105
36. Sarzi-Puttini P., Atzeni F., Randisi G., et al. Successful treatment of resistant Behcet's disease with etanercept. Ann Rheum Dis 532 (2004) (abstract AB0100)
37. Scheinberg M.A. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol 20 (2002) 733-734
38. Estrach C., Mpofu S., and Moots R.J. Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 41 (2002) 1213-1214
39. Goossens P.H., Verburg R.J., and Breedveld F.C. Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 60 (2001) 637
40. Gulli S., Arrigo C., Bocchino L., et al. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 4 (2003) 19
41. Haugeberg G., Velken M., and Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 63 (2004) 744-745
42. Katsiari C.G., Theodossiadis P.G., Kaklamanis P.G., et al. Successful long-term treatment of refractory Adamantiades-Behcet's disease (ABD) with infliximab: report of two patients. Adv Exp Med Biol 528 (2003) 551-555
43. Robertson L.P., and Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford) 40 (2001) 473-474
44. Rozenbaum M., Rosner I., and Portnoy E. Remission of Behcet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 61 (2002) 283-284
45. Saulsbury F.T., and Mann J.A. Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum 49 (2003) 599-600
46. Hassard P.V., Binder S.W., Nelson V., et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 120 (2001) 995-999
47. Mussack T., Landauer N., Ladurner R., et al. Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab. Am J Gastroenterol 98 (2003) 703-704
48. Travis S.P., Czajkowski M., McGovern D.P., et al. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49 (2001) 725-728
49. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358 (2001) 295-296
50. Ohno S., Nakamura S., Hori S., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31 (2004) 1362-1368
51. Triolo G., Vadala M., Accardo-Palumbo A., et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 61 (2002) 560-561
52. Andonopoulos A.P., Meimaris N., Daoussis D., et al. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behcet's disease. Clin Exp Rheumatol 21 suppl 4 (2003) S57-S58
53. Ribi C., Sztajzel R., Delavelle J., et al. Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry 76 (2005) 1733-1735
54. Sarwar H., McGrath Jr. H., and Espinoza L.R. Successful treatment of long-standing neuro-Behcet's disease with infliximab. J Rheumatol 32 (2005) 181-183
55. Yucel A.E., Kart-Koseoglu H., Akova Y.A., et al. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Rheumatology (Oxford) 43 (2004) 394-396
56. Seider N., Beiran I., Scharf J., et al. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol 85 (2001) 1287-1288
57. Rispo A., Scarpa R., Di Girolamo E., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 34 (2005) 387-391
58. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52 (2005) 601-607
59. Chiappetta N., Steier J., and Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 11 (2005) 264-266
60. Noss E.H., Hausner-Sypek D.L., and Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33 (2006) 1021-1026
61. Chung L., and Fiorentino D. An open-label trial of rituximab in the treatment of patients with dermatomyositis. J Am Acad Dermatol 54 (2006) AB77 (poster abstract)
62. Efthimiou P., Schwartzman S., and Kagen L. Possible role for TNF-inhibitors in the treatment of resistant dermatomyositis and polymyositis. Ann Rheum Dis 65 (2006) 1233-1236
63. Norman R., Greenberg R.G., and Jackson J.M. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 54 suppl (2006) S139-S142
64. Saadeh C. Etanercept is effective in the treatment of polymyositis. Arthritis Rheum 43 (2000) s193
65. Hengstman G.J., van den Hoogen F.H., Barrera P., et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50 (2003) 10-15
66. Roddy E., Courtney P.A., and Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 41 (2002) 1194-1195
67. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 329 (1993) 1993-2000
68. Dalakas M.C. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol 6 (2006) 550-556
69. Mosca M., Stringini F., Carmignani A., et al. Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy. Arthritis Rheum 53 (2005) 119-121
70. Boogaard R., Drexhage V.R., and van Suijlekom-Smit L.W. Two children with skin rash and muscle weakness: juvenile dermatomyositis. Ned Tijdschr Geneeskd 149 (2005) 146-150
71. Wetter D.A., Davis M.D., Yiannias J.A., et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 80 (2005) 41-47
72. Cherin P., Herson S., Wechsler B., et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory PM and dermatomyositis: an open study with 20 patients. Am J Med 91 (1991) 162-167
73. Mastaglia F.L., Phillips B.A., and Zilko P.J. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 65 (1998) 107-110
74. De Vita S., Ferraccioli G.F., Di Poi E., et al. High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. Clin Exp Rheumatol 14 suppl 15 (1996) S85-S92
75. Gottfried I., Seeber A., Anegg B., et al. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10 (2000) 29-35
76. Danieli M.G., Malcangi G., Palmieri C., et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61 (2002) 37-41
77. Lang B., Laxer R.M., Murphy G., et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91 (1991) 169-172
78. Barron K.S., Sher M.R., and Silverman E.D. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol 33 Suppl (1992) 94-97
79. Sansome A., and Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases. Arch Dis Child 72 (1995) 25-28
80. Tsai M.J., Lai C.C., Lin S.C., et al. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Acta Paediatr Sin 38 (1997) 111-115
81. Al-Mayouf S.M., Laxer R.M., Schneider R., et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27 (2000) 2498-2503
82. Fields K.S., Petersen M.J., Chiao E., et al. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG). J Drugs Dermatol 4 (2005) 510-513
83. Kalavala M., Motley R., and Khan S. Successful treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin (IVIg). J Am Acad Dermatol 54 (2006) AB137 (poster abstract)
84. Schmidt E., Benoit S., Brocker E.B., et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 142 (2006) 147-150
85. Minni J., and Sarro R. A novel therapeutic approach to erythema annulare centrifugum. J Am Acad Dermatol 54 suppl (2006) S134-S135
86. Wenkler T.R., Gottwald L.D., and Thomas J. Recalcitrant erythema nodosum treated successfully with alefacept (2005) 63rd Annual Meeting of the American Academy of Dermatology February 18-22, 2005 New Orleans, LA
87. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft versus host disease. Biol Blood Marrow Transplant 11 (2005) 680-687
88. Andolina M., Rabusin M., Maximova N., et al. Etanercept in graft-versus-host disease. Bone Marrow Transplant 26 (2000) 929
89. Wolff D., Roessler V., Steiner B., et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 35 (2005) 1003-1010
90. Couriel D., Hicks K., and Ipolotti C. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: an update. Blood 96 (2000) 400a (abstract)
91. Kobbe G., Schneider P., Rohr U., et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 28 (2001) 47-49
92. Reidi I., Knoche J., Tanner A.R., et al. Salvage therapy with infliximab for patients with severe acute and chronic GVHD [abstract]. Blood 98 Suppl (2001) 399a
93. Yamane T., Yamamura R., Aoyama Y., et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma 44 (2003) 2095-2097
94. Jacobsohn D.A., Hallick J., Anders V., et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 74 (2003) 119-124
95. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104 (2004) 649-654
96. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89 (2004) 1352-1359
97. Antin J.H., Chen A.R., Couriel D.R., et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 10 (2004) 655-668
98. Shapira M.Y., Resnich I.B., Bitan M., et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 36 (2005) 1097-1101
99. Carpenter P.A., Lowder J., Johnston L., et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 465-471
100. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9 (2003) 505-511
101. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 (2004) 2603-2606
102. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood 108 (2006) 756-762
103. Redei I., and Tanner A.R. Salvage therapy with infliximab for patients with severe acute and chronic GVHD. KJ. Blood 98 suppl 1 (2001) 399a (abstract)
104. Chiang K.Y., Abhyankar S., Bridges K., et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73 (2002) 665-667
105. Hertl M.S., Haendle I., Schuler G., et al. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumor necrosis factor-alpha inhibitor, infliximab. Br J Dermatol 152 (2005) 552-555
106. Goffe B.S. Disseminated granuloma annulare resolved with the T-cell modulator efalizumab. Arch Dermatol 140 (2004) 1287-1288
107. Sullivan T.P., Welsh E., Kerdel F.A., et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 149 (2003) 1046-1049
108. Adams D.R., Gordon K.B., Devenyi A.G., et al. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 139 (2003) 1540-1542
109. Katsanos K.H., Christodoulou D.K., and Tsianos E.V. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 97 (2002) 2155-2156
110. Lebwohl B., and Sapadin A.N. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 49 suppl (2003) S275-S276
111. Martinez F., Nos P., Benlloch S., et al. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 7 (2001) 323-326
112. Rosi Y.L., Lowe L., and Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 16 (2005) 58-61
113. Roussomoustakaki M., Dimoulios P., Chatzicostas C., et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 38 (2003) 1000-1004
114. Sansbury J.J., and Fleischer A.B. Clinical improvement of treatment-refractory hidradenitis suppurativa with etanercept (2004) 62nd Annual Meeting of the American Academy of Dermatology; Washington, DC
115. Armario-Hita J.C., and Fernandez-Vozmediano J.M. Infliximab for the treatment of suppurative chronic hidradenitis. J Am Acad Dermatol 54 (2006) AB57 (poster abstract)
116. Rosi Y.L., Lowe L., and Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatol Treat 16 (2005) 58-61
117. Cusack C., and Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 154 (2006) 726-729
118. Jurgensmeyer J.C. Clinical improvement of refractory hidradenitis with etanercept. J Am Acad Dermatol 50 (2004) P15 (abstract)
119. Robins D. Successful treatment of hidradenitis suppurative with efalizumab: a case report. J Am Acad Dermatol 54 (2006) AB74 (poster abstract)
120. Goo B., Chung K.Y., Chung W.G., et al. Intramuscular immunoglobulin for recalcitrant suppurative skin diseases. J Am Acad Dermatol 54 (2006) AB58 (poster abstract)
121. Carmeli Y., Mevorach D., Kaminski N., et al. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer 73 (1994) 2859-2861
122. Burns J.D., Mason W.H., Hauger S.B., et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146 (2005) 662-667
123. Graves J., Smith D., and Heffernan M. A single center, open-label, pilot study evaluating the safety and effectiveness of efalizumab in the treatment of oral lichen planus. J Am Acad Dermatol 54 (2006) AB64 (poster abstract)
124. Fivenson D.P., and Mathes B. Treatment of generalized lichen planus with alefacept. Arch Dermatol 142 (2006) 151-152
125. Cauza K., Hinterhuber G., Sterniczky B., et al. Unusual clinical manifestation of linear IgA dermatosis: a report of two cases. J Am Acad Dermatol 51 Suppl (2004) S112-S117
126. Gluth M.B., Witman P.M., and Thompson D.M. Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis. Int J Pediatr Otorhinolaryngol 68 (2004) 965-970
127. Goebeler M., Seitz C., Rose C., et al. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol 149 (2003) 912-914
128. Letko E., Bhol K., Foster C.S., et al. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology 107 (2000) 1524-1528
129. Kroiss M.M., Vogt T., Landthaler M., et al. High-dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol 142 (2000) 582 (published erratum appears in Br J Dermatol 142(6):1268, 2000)
130. Khan I.U., Bhol K.C., and Ahmed A.R. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. J Am Acad Dermatol 40 (1999) 485-488
131. Ulmer A., Kotter I., Pfaff A., et al. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol 46 (2002) 123-127
132. Christopher-Stine L., and Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol 30 (2003) 2725-2727
133. Sellam J., Deslandre C.J., Dubreuil F., et al. Refractory multicentric reticulohistiocytosis treated by infliximab: two cases. Clin Exp Rheumatol 23 (2005) 97-99
134. Lee M.W., Lee E.Y., Jeong Y.I., et al. Successful treatment of multicentric reticulohistiocytosis with a combination of infliximab, prednisolone and methotrexate. Acta Derm Venereol 84 (2004) 478-479
135. Kovach B.T., Calamia K.T., Walsh J.S., et al. Treatment of multicentric reticluohistocytosis with etanercept. Arch Dermatol 140 (2004) 919-921
136. Matejicka C., Morgan G.J., and Schlegelmilch J.G. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman, et al. Arthritis Rheum 48 (2003) 864-866
137. Lovelace K., Loyd A., Adelson D., et al. Etanercept and the treatment of multicentric reticulohistiocytosis. Arch Dermatol 141 (2005) 1167-1168
138. Shannon S.E., Schumacher H.R., Self S., et al. Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient. J Rheumatol 32 (2005) 565-567
139. Kolde G., Muche J.M., Schulze P., et al. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology 206 (2003) 180-181
140. Cummins D.L., Hiatt K.M., Mimouni D., et al. Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy. Int J Dermatol 43 (2004) 852-854
141. Zeichner J., Stern D., and Lebwohl M. Intralesional etanercept for the treatment of necrobiosis lipoidica. J Am Acad Dermatol 54 (2006) AB57 (poster abstract)
142. Zeichner J.A., Stern D.W.K., and Lebwohl M. Case letters. J Am Acad Dermatol 54 suppl (2006) S120-S121
143. Chung H.J., and Chung K.Y. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150 (2004) 596-597
144. Foster C.S., and Ahmed A.R. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 106 (1999) 2136-2143
145. Jolles S. High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol 129 (2002) 385-389
146. Urcelay M.L., McQueen A., and Douglas W.S. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol 137 (1997) 477-478
147. Letko E., Bhol K., Foster S.C., et al. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid: a correlation with disease activity: a preliminary study. Curr Eye Res 21 (2000) 646-654
148. Ahmed A.R., and Colon J.E. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 137 (2001) 1181-1189
149. Sami N., Bhol K.C., and Ahmed A.R. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 102 (2002) 59-67
150. Sami N., Bhol K.C., and Ahmed A.R. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy: long term follow-up: influence of treatment on antibody titres to human alpha6 integrin. Clin Exp Immunol 129 (2002) 533-540
151. Leverkus M., Gerogi M., Nie Z., et al. Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. J Am Acad Dermatol 46 (2002) 116-122
152. Yeh S.W., Usman A.Q., and Ahmed A.R. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol 112 (2004) 268-272
153. Sami N., Letko E., Androudi S., et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 111 (2004) 1380-1382
154. Daoud Y., Amin K.G., Mohan K., et al. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study. Ann Pharmacother 39 (2005) 2003-2008
155. Sacher C., Rubbert A., Konig C., et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 46 (2002) 113-115
156. Labrecque P., and Null M. Cicatricial pemphigoid and therapy with the TNF inhibitor etanercept. J Am Acad Dermatol 50 (2004) P48 (abstract)
157. Harman K.E., and Black M.M. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: and evaluation of its use in 14 cases. Br J Dermatol 140 (1999) 865-874
158. Beckers R.C., Brand A., Vermeer B.J., et al. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 133 (1995) 289-293
159. Ahmed A.R. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45 (2001) 825-835
160. Sami N., Ali S., Bhol K.C., et al. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 17 (2003) 641-645
161. Yamauchi P.S., Lowe N.J., Gindi V., et al. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 54 suppl (2006) S121-S122
162. Harman K.E., and Black M.M. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 140 (1999) 865-874
163. Salopek T.G., Logsetty S., and Tredget E.E. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 47 (2002) 785-788
164. Dupuy A., Viguier M., Bedane C., et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140 (2004) 91-96
165. Goebeler M., Herzog S., Brocker E.B., et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 149 (2003) 899-901
166. Herrmann G., Hunzelmann N., and Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 148 (2003) 602-603
167. Cooper H.L., Healy E., Theaker J.M., et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol 28 (2003) 366-368
168. Espana A., Fernandez-Galar M., Lloret P., et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 50 (2004) 974-976
169. Virgolini L., and Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica 88 (2003) ELT24
170. Arin M.J., Engert A., Krieg T., et al. Anti-CD20 monoclonal antibody (Rituximab) in the treatment of pemphigus. Br J Dermatol 153 (2005) 620-625
171. Schmidt E., Herzog S., and Brocker E.B. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 153 (2005) 449-451
172. Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (Rituximab). J Am Acad Dermatol 51 (2004) 817-819
173. Pitarch G., Sanchez-Carazo J.L., Pardo J., et al. Treatment of severe refractory pemphigus vulgaris with rituximab. Actas Dermosifiligr 97 (2006) 48-51
174. Kong H.H., Prose N.S., Ware R.E., et al. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 22 (2005) 461-464
175. Lin M.H., Hsu C.K., and Lee J.Y.Y. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 141 (2005) 680-682
176. Tappeiner G., and Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 20 (1989) 684-685
177. Humbert P., Derancourt C., Aubin F., et al. Effects of intravenous gamma-globulin in pemphigus. J Am Acad Dermatol 22 (1990) 326 (letter)
178. Messer G., Sizmann N., Feucht H., et al. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 133 (1995) 1014-1016
179. Bewley A.P., and Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 135 (1996) 128-129
180. Weaver S., Zillikens D., and Brocker E.B. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 135 (1996) 862-863
181. Colonna L., Cianchini G., Frezzolini A., et al. Intravenous immunoglobulin for pemphigus vulgaris: adjuvant or first choice therapy?. Br J Dermatol 138 (1998) 1102-1103
182. Jolles S., Hughs J., and Rustin M. Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris. J Am Acad Dermatol 40 (1999) 499-500
183. Engineer L., Norton L.A., and Ahmed A.R. Nail involvement in pemphigus vulgaris. J Am Acad Dermatol 43 (2000) 529-535
184. Ahmed A.R. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45 (2001) 679-690
185. Sami N., Qureshi A., Ruocco E., et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 138 (2002) 1158-1162
186. Bystryn J.C., Jiao D., and Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 47 (2002) 358-363
187. Sibaud V., Beylot-Barry M., Doutre M.S., et al. Successful treatment of corticoid-resistant pemphigus with high-dose intravenoud immunoglobulins. Ann Dermatol Vernereol 127 (2000) 408-410
188. Levy A., Doutre M.S., Lesage F.X., et al. Treatment of pemphigus with intravenous immunoglobulin. Ann Dermatol Venereol 131 (2004) 957-961
189. Nieves Renteria A., Ochoa Fierro J.G., Martinez Ordaz V.A., et al. Treatment with high doses of intravenous immunoglobulin in a case of complicated pemphigus vulgaris. Rev Alerg Mex 52 (2005) 39-41
190. Szep Z., Danilla T., and Buchvald D. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins]. Cas Lek Cesk 144 (2005) 700-703
191. Sami N., Bhol K.C., and Ahmed A.R. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105 (2002) 192-198
192. Ahmed A.R., and Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 46 (2002) 42-49
193. Daoud Y.J., Foster C.S., and Ahmed R. Eyelid skin involvement in pemphigus foliaceus. Ocul Immunol Inflamm 13 (2005) 389-394
194. Sami N., Qureshi A., and Ahmed A.R. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol 12 (2002) 174-178
195. Toth G.G., and Jonkman M.F. Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins. Br J Dermatol 141 (1999) 583-585
196. Beckers R.C., Brand A., Vermeer B.J., et al. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 133 (1995) 289-293
197. Ahmed A.R., Avram M.M., and Duncan L.M. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med 349 (2003) 382-391
198. Borradori L., Lombardi T., Samson J., et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137 (2001) 269-272
199. Heizmann M., Itin P., Wernli M., et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66 (2001) 142-144
200. Rossum M.M., Verhaegen N.T., Jonkman M.F., et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk Lymphoma 45 (2004) 2327-2332
201. Schadlow M.B., Anhalt G.J., and Sinha A.A. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2 (2003) 564-567
202. Barnadas M., Roe E., Brunet S., et al. Therapy of Paraneoplastic pemphigus with rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol 20 (2006) 69-74
203. Mitra A., and Goodfield M. A case of pityriasis rubra pilaris associated with arthropathy treated with infliximab. J Am Acad Dermatol 54 (2006) AB198 (poster abstract)
204. Liao W.C., and Mutasim D.F. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 141 (2005) 423-425
205. Drosou A., Kirsner R.S., Welsh E., et al. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 7 (2003) 382-386
206. Flores M.G., Ruelas M.H., Lozano O.W., et al. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. J Am Acad Dermatol 54 (2006) AB183 (poster abstract)
207. Fazekas Z., Kantor I., and Lebwohl M. A patient with pityriasis rubra pilaris responds to therapy with alefacept. J Am Acad Dermatol 54 (2006) AB198 (poster abstract)
208. Creamer D., McGregor J.M., and Hawk J.L. Polymorphic light eruption occurring in common variable hypogammaglobulinaemia, and resolving with intravenous immunoglobulin therapy. Clin Exp Dermatol 24 (1994) 273-274
209. Antonelli A., Navarranne A., Palla R., et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 4 (1994) 399-408
210. Lami M.C., Vabres P., Dreyfus B., et al. Primary cutaneous B-cell lymphoma mimicking pyoderma gangrenosum: first-line treatment with rituximab. Br J Dermatol 151 (2004) 250-252
211. Heinzerling L., Dummer R., Kempf W., et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 136 (2000) 374-378
212. Paul T., Radny P., Krober S.M., et al. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 144 (2001) 1239-1243
213. Roguedas A.M., Watier H., Paintaud G., et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Br J Dermatol 152 (2005) 541-544
214. Wingh F., and Weinberg J.M. Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma. Cutis 76 (2005) 186-188
215. Gurmin V., Mediwake R., Fernando M., et al. Psoriasis: response to high-dose intravenous immunoglobulin in three patients. Br J Dermatol 147 (2002) 554-557
216. Regueiro M., Valentine J., Plevy S., et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98 (2003) 1821-1826
217. Ljung T., Staun M., Grove O., et al. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 37 (2002) 1108-1110
218. Arnott I.D., McDonald D., Williams A., et al. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 15 (2001) 1639-1646
219. Batres L.A., Mamula P., and Baldassano R.N. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 34 (2002) 558-560
220. Botros N., Pickover L., and Das K.M. Image of the Month. Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology 118 (2000) 654-809
221. Grange F., Djilali-Bouzina F., Weiss A.M., et al. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 205 (2002) 278-280
222. Jenne L., Sauter B., Thumann P., et al. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody). Br J Dermatol 150 (2004) 380-382
223. Kugathasan S., Miranda A., Nocton J., et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 37 (2003) 150-154
224. Mimouni D., Anhalt G.J., Kouba D.J., et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 148 (2003) 813-816
225. Romero-Gomez M., and Sanchez-Munoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol 14 (2002) 907
226. Sapienza M.S., Cohen S., and Dimarino A.J. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci 49 (2004) 1454-1457
227. Sheldon D.G., Sawchuk L.L., Kozarek R.A., et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 135 (2000) 564-568 discussion 8-9
228. Singh M., Andrew S.M., and Lear J.T. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol 29 (2004) 196-197
229. Tan M.H., Gordon M., Lebwohl O., et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137 (2001) 930-933
230. Triantafillidis J.K., Cheracakis P., Sklavaina M., et al. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 37 (2002) 863-865
231. Zaccagna A., Bertone A., Puiatti P., et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol 13 (2003) 258-260
232. th, Johnson CA, Lynn A: Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 3:441-444, 04
233. Kiran R.P., O'Brien-Ermlich B., Achkar J.P., et al. Management of peristomal pyodermal gangrenosum. Dis Colon Rectum 48 (2005) 1397-1403
234. Swale V.J., Saha M., Kapur N., et al. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol 30 (2005) 134-136
235. Brooklyn T.N., Dunnill M.G., Shetty A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 55 (2006) 505-509
236. Hubbard V.G., Friedmann A.C., and Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 152 (2005) 1059-1061
237. Roy D.B., Conte E.T., and Cohen D.J. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol 54 suppl (2006) S128-S133
238. Goldenberg G., and Jorizzo J.L. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat 16 (2005) 347-349
239. Pastor N., Betlloch I., Pascual J.C., et al. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol 31 (2006) 152-153
240. Woodson J. Use of efalizumab for the successful treatment of chronic recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 54 (2006) AB77 (poster abstract)
241. Feldman S., McCarty M.A., Carroll C., et al. The use of alefacept for the treatment of pyoderma gangrenosum. J Am Acad Dermatol 54 (2006) AB226 (poster abstract)
242. Suchak R., Glover M., and Lawlor F. Intravenous immunoglobulin is effective as a sole immunomodulatory agent in pyoderma gangrenosum unresponsive to systemic corticosteroids. J Am Acad Dermatol 54 (2006) AB241 (poster abstract)
243. Gupta A.K., Shear N.H., and Sauder D.N. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 32 (1995) 140-142
244. Dirschka T., Kastner U., Behrens S., et al. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol 39 (1998) 789-790
245. Hagman J.H., Carrozzo A.M., Campione E., et al. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatol Treat 12 (2001) 19-22
246. Dobson C.M., Parslew R.A., and Evans S. Superficial granulomatous pyoderma treated with intravenous immunoglobulin. J Am Acad Dermatol 48 (2003) 456-460
247. Roberts S.D., Wilkes D.S., Burgett R.A., et al. Refractory sarcoidosis responding to infliximab. Chest 124 (2003) 2028-2031
248. Haley H., Cantrell W., and Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 150 (2004) 146-149
249. Meyerle J.H., and Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2 (2003) 413-414
250. Baughman R.P., and Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 70-74
251. Mallbris L., Ljungberg A., Hedblad M.A., et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 48 (2003) 290-293
252. Khanna D., Liebling M.R., and Louie J.S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 30 (2003) 1864-1867
253. Heffernan M.P., and Smith D.I. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142 (2006) 17-19
254. Callejas-Rubio J.L., Ortego-Centeno N., Lopez-Perez L., et al. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25 (2006) 596-597
255. Baughman R., Lo K., Guzzo C., et al. Efficacy of infliximab in improving lupus pernio in patients receiving treatment for chronic pulmonary sarcoidosis. J Am Acad Dermatol 54 (2006) AB13 (poster abstract)
256. Sweiss N.J., Welsch M.J., Sawaqed R., et al. Infliximab in refractory sarcoidosis, long term follow up (2005) 8th Meeting of the World Association of Sarcoidosis and other Granulomatous Disorders June 12-15, Denver, CO T15 (abstract)
257. Sweiss N.J., Sawaqed R., and Curran J.L. Infliximab induced hyperglycemia in a patient with refractory sarcoidosis, adalimumab (2005) 8th Meeting of the World Association of Sarcoidosis and other Granulomatous Disorders June 12-15, Denver, CO T13 (abstract)
258. Doty J.D., Mazur J.E., and Judson M.A. Treatment of sarcoidosis with infliximab. Chest 127 (2005) 1064-1071
259. Chi G.C., Hsu F.S., Yang C.C., et al. Scleroderma and failed response to alefacept. Rheumatology (Oxford) 44 (2005) 1328-1330
260. Ellman M.H., MacDonald P.A., Hayes F.A., et al. Etanercept as a treatment for diffuse scleroderma: a pilot study. Arthritis Rheum 43 supp (2000) S392 (abstract)
261. Bargagli E, Galeazzi M, Bellisai F: Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Repiration, in press
262. Welsh E., Kerdel F.A., and Kirsner R.S. Skin and lung improvement in a patient with scleroderma treated with anti-TNF medications and mycophenolate mofetil (2005) 63rd Annual Meeting of the American Academy of Dermatology; New Orleans, LA
263. Menon Y., Cucurull E., and Espinoza L.R. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology (Oxford) 42 (2003) 1273-1274 (letter)
264. Asano Y., Ihn H., Asashima N., et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford) 44 (2005) 824-826
265. Levy Y., Amital H., Langevitz P., et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 50 (2004) 1005-1007
266. Amital H., Rewald E., Levy Y., et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 62 (2003) 175-177
267. Wojas-Pelc A., Blaszczyk M., Glinska M., et al. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 19 (2005) 462-465
268. Shergill B., Orteu C.H., McBride S.R., et al. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol 153 (2005) 650-652
269. Kulczycki A., Nelson M., Eisen A., et al. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 149 (2003) 1276-1281
270. Lister R., Jolles S., Whittaker, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 43 (2000) 403-408
271. Kumar N., and Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler 10 (2004) 85-86
272. Karim A., Lawlor F., and Black M.M. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 29 (2004) 317-318
273. Righi A., Schiavon F., Jablonska S., et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 61 (2002) 59-61
274. Majeski C., Taher M., Grewal P., et al. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg 9 (2005) 99-104
275. Pasternack F.P., Fox L.P., and Engler D.E. Silicone granulomas treated with etanercept. Arch Dermatol 141 (2005) 13-15
276. Voigtlander C., Luftl M., Schuler G., et al. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 137 (2001) 1571-1574
277. Bonifati C., Trento E., Cordiali Fei P., et al. Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids. Clin Exp Dermatol 30 (2005) 662-665
278. Kreuter A., Hyun J., Altmeyer P., et al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 85 (2005) 545-547
279. Yamauchi P.S., Turner L., Lowe N.J., et al. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 54 suppl (2006) S122-S125
280. Rahier J.F., Lion L., Dewit O., et al. Regression of Sweet's syndrome associated with Crohn's disease after anti-tumor necrosis factor therapy. Acta Gastroenterol Belg 68 (2005) 376-379
281. Foster E.N., Nguyen K.K., Sheikh R.A., et al. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol 12 (2005) 145-149
282. Haliasos E., Soder B., Rubenstein D.S., et al. Pediatric Sweet syndrome and immunodeficiency successfully treated with intravenous immunoglobulin. Pediatr Dermatol 22 (2005) 530-535
283. Prins C., Kerdel F.A., Padilla R.S., et al., TEN-IVIG Study Group. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139 (2003) 26-32
284. Bachot N., Revuz J., and Roujeau J.C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139 (2003) 33-36
285. Trent J.T., Kirsner R.S., Romanelli P., et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 139 (2003) 39-43
286. Shortt R., Gomez M., Mittman N., et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25 (2004) 246-255
287. Lissia M., Figus A., and Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 58 (2005) 504-510
288. Tan A.W., Thong B.Y., Yip L.W., et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 32 (2005) 1-6
289. Nasser M., Bitterman-Deutsch O., and Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci 329 (2005) 95-98
290. Neff P., Meuli-Simmen C., Kempf W., et al. Lyell syndrome revisited: analysis of 18 cases of severe bullous skin disease in a burns unit. Br J Plast Surg 58 (2005) 73-80
291. Jones B., Vun Y., Sabah M., et al. Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol 46 (2005) 187-191
292. Arca E., Kose O., Erbil A.H., et al. A 2-year-old girl with Stevens-Johnson syndrome/toxic epidermal necolysis treated with intravenous immunoglobulin. Pediatr Dermatol 22 (2005) 317-320
293. Spornraft-Ragaller P., Theilen H., Gottschlich G.S., et al. [Treatment of toxic epidermal necrolysis experience with 9 patients with consideration of intravenous immunoglobulin]. Hautarzt 57 (2006) 185-194
294. Kim K.J., Lee D.P., Suh H.S., et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 85 (2005) 497-502
295. Mangla K., Rastogi S., Goyal P., et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 71 (2005) 398-400
296. Faye O., and Roujeau J.C. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg): clinical experience to date. Drugs 65 (2005) 2085-2090
297. French L.E., Trent J.T., and Kerdel F.A. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 6 (2006) 543-549
298. Fischer M., Fiedler E., Marsch W.C., et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146 (2002) 707-709
299. Dawn G., Urcelay M., Ah-Weng A., et al. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol 149 (2003) 836-840
300. Kerr H., and Lim H.W. Recalcitrant delayed pressure urticaria treated with intravenous immunoglobulin. J Am Acad Dermatol 54 (2006) AB60 (poster abstract)
301. O'Donnell B.F., Barr R.M., Kobza Black A.K., et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 138 (1998) 101-106
302. Asero R. Is IVIG for chronic unremitting urticaria effective?. Allergy 55 (2000) 1099-1101
303. Kroiss M., Vogt T., Landthaler M., et al. The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. Acta Derm Venereol 80 (2000) 225
304. Darras S., Segard M., Mortier L., et al. [Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy]. Ann Dermatol Venereol 131 (2004) 65-69
305. Puech-Plottova I., Michel J.L., Rouchouse B., et al. [Solar urticaria: one case treated by intravenous immunoglobulin]. Ann Dermatol Venereol 127 (2000) 831-835
306. Orson F.M. Intravenous immunoglobulin therapy suppresses manifestations of the angioedema with hypereosinophilia syndrome. Am J Med Sci 326 (2003) 94-97
307. Raza K., Carruthers D.M., Stevens R., et al. Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. Ann Rheum Dis 65 (2006) 946-948
308. Ong C.S., and Benson E.M. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol 143 (2000) 447-449
309. Sais G., Vidaller A., Servitje O., et al. Leukocytoclastic vasculitis and common variable immunodeficiency: successful treatment with intravenous immune globulin. J Allergy Clin Immunol 98 (1996) 232-233
310. Kreuter A., Gambichler T., Breuckmann F., et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 51 (2004) 574-579
311. Schanz S., Ulmer A., and Fierlbeck G. Intravenous immunoglobulin in livedo vasculitis: a new treatment option?. J Am Acad Dermatol 49 (2003) 555-556
312. Ravat F.E., Evans A.V., and Russell-Jones R. Response of livedoid vasculitis to intravenous immunoglobulin. Br J Dermatol 147 (2002) 166-169
313. Amital H., Levy Y., and Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 18 (2000) 404-406
314. Levy Y., Sherer Y., George J., et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 119 (1999) 231-238
315. Tan A.L., Holdsworth J., Pease C., et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62 (2003) 373-374
316. Airo P., Antonioli C.M., Vianelli M., et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41 (2002) 347-349
317. Arbach O., Gross W.L., and Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206 (2002) 496-501
318. Hoffman G.S., Merkel P.A., Brasington R.D., Lenschow D.J., et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50 (2004) 2296-2304
319. Basse G, Ribes D, Kamar N, et al: Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 80:1560-1564
320. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
321. Lamprecht P., Moosig F., Adam-Klages S., et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 63 (2004) 1518-1520
322. Mang R., Ruzicka T., and Stege H. Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol 51 (2004) 321-322
323. Weiss J.E., Eberhard B.A., Chowdhury D., et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31 (2004) 808-810
324. Stone J.H. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
325. Keystone E.C. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis 63 suppl (2004) ii79-ii83
326. Stone J.H., Uhlfelder M.L., Hellmann D.B., et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44 (2001) 1149-1154
327. Feinstein J., and Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 11 (2005) 219-222
328. Booth A., Harper L., Hammad T., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
329. Booth A.D., Jefferson H.J., Ayliffe W., et al. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 61 (2002) 559
330. Lamprecht P., Voswinkel J., Lilienthal T., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41 (2002) 1303-1307
331. Gause A., Arbach O., Reinhold-Keller E., et al. Induction of remission with infliximab in active generalized Wegener's Granulomatosis is effective but complicated by serious infection. Arthritis Rheum 48 (2003) s208 (abstract)
332. Al-Bishri J., le Riche N., and Pope J.E. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 32 (2005) 1371-1373
333. Jayne D.R., Chapel H., Adu D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93 (2000) 433-439
334. Jayne D.R., and Lockwood C.M. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35 (1993) 1150-1153
335. Jayne D.R., Esnault V.L., and Lockwood C.M. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 6 (1993) 207-219
336. Richter C., Schnabel A., Csernok E., et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101 (1995) 2-7
337. Adlakha A., Rao K., Adlakha K., et al. A case of pediatric Wegener's granulomatosis with recurrent venous thromboses treated with intravenous immunoglobulin and laryngotracheoplasty. Pediatr Pulmonol 20 (1995) 265-268
338. Tuso P., Moudgil A., Hay J., et al. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 20 (1992) 504-508
339. Levy Y., Sherer Y., George J., et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 119 (1999) 231-238
340. Finkel TH, Torok TJ, Ferguson PJ, et al: Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 343:1255-1258, 94
341. Asano Y., Ihn H., Maekawa T., et al. High-dose intravenous immunoglobulin infusion in polyarteritis nodosa. Clin Rheumatol 25 (2006) 396-398
342. Gedalia A., Correa H., Kaiser M., et al. Case report: steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis. Am J Med Sci 309 (1995) 226-228
343. Uziel Y., and Silverman E.D. Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa. Clin Exp Rheumatol 16 (1998) 187-189
344. Kroiss M., Hohenleutner U., Gruss C., et al. Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa. Dermatology 203 (2001) 188-189
345. Machet L., Vincent O., Machet M.C., et al. Cutaneous periarteritis nodosa resistant to combined corticosteroids and immunosuppressive agents. Efficacy of treatment with intravenous immunoglobulins. Ann Dermatol Venereol 122 (1995) 769-772
346. Viguier M., Guillevin L., and Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 344 (2001) 1481-1482
347. Finkel T.H., Torok T.J., Ferguson P.J., et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?. Lancet 343 (1994) 1255-1258
348. Kallenbach M., Duan H., and Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 99 (2005) c92-c96
349. Omdal R., Wildhagen K., Hansen T., et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis; favourable but temporary response. Scand J Rheumatol 34 (2005) 229-232
350. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257 (2005) 540-548
351. Aries P.M., Hellmich B., Both M., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65 (2006) 853-858
352. Keogh K.A., Ytterberg S.R., Fervenza F.C., et al. Rituximab for refractory Wegener's granulomatosis: resport of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
353. Keogh K.A., Wylam M.E., Stone J.H., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268